Carlsmed enters its May 7 earnings report with the Street firmly bullish in rating but quietly walking back targets — a gap that now defines the most interesting tension into the print.
Covering analysts at Goldman Sachs and Truist Securities both trimmed price targets in April while keeping Buy ratings. Goldman cut from $19 to $17 on April 9; Truist followed on April 15, moving from $20 to $18. Neither abandoned the thesis. The consensus mean target still sits near $18.60 — roughly double the current price of $8.92, a stock down 8% over the past month and off 26% year-to-date. BTIG reiterated a Buy with a $24 target in December. Every covering analyst rates CARL a Buy or Overweight. The direction of travel on targets, however, is consistently downward.
The bull case rests on Carlsmed's AI-enabled personalized spine implant platform, Aprevo, which has demonstrated strong third-party reimbursement and attractive hospital economics in lumbar fusion. The expansion into cervical spine surgery is the next growth lever. Bears question whether that expansion proves harder than lumbar: traditional cervical fusion has a high baseline success rate, which narrows the clinical argument for a custom implant, and securing dedicated reimbursement codes for cervical procedures adds another layer of execution risk for a company that remains pre-profitability with negative earnings yield and EV/EBITDA.
Short positioning offers little edge either way. At 2.1% of free float — down sharply from a mid-April peak above 2.8% — short interest is modest and has been contracting. Cost to borrow has eased more than 33% over the past month to roughly 2.5%, and borrow availability remains relatively wide. None of that signals a crowded short or any meaningful squeeze dynamic. The ORTEX short score of 51.7 is effectively neutral.
Past prints show a mixed reaction profile. February's Q4 report produced an 11.5% single-day pop, but the gain faded to nearly flat within five sessions. April's update produced a 2.2% one-day drop and a 5.9% five-day loss. Thursday's print tests whether Aprevo's utilisation trajectory and the cervical launch timeline can close the gap between a stock trading near $9 and a Street consensus anchored closer to $18.
See the live data behind this article on ORTEX.
Open CARL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
